

# A New Era in Targeting Multiple Pathways in Advanced Breast Cancer


IMPAKT 2013 Industry Satellite Symposium

Friday, 3 May 2013

12.15-13.15

## Silver Hall

SQUARE Brussels Meeting Centre  
Museumstraat/8 rue du Musée  
B-1000 Brussels



# A New Era in Targeting Multiple Pathways in Advanced Breast Cancer

IMPAKT 2013 Industry  
Satellite Symposium

Friday, 3 May 2013  
12.15-13.15

## Silver Hall

SQUARE Brussels Meeting Centre  
Museumstraat/8 rue du Musée  
B-1000 Brussels

## Chair

Sunil Verma, MD, MEd, FRCPC  
Toronto Sunnybrook Regional Cancer Center  
Toronto, Ontario, Canada

## Faculty

Sara Hurvitz, MD  
UCLA Jonsson  
Comprehensive Cancer Center  
Los Angeles, California, United States

Nicholas Turner, MA, MRCP, PhD  
Institute of Cancer Research  
London, United Kingdom

## Agenda

Friday, 3 May 2013

- Welcome and introduction  
*Sunil Verma, MD, MEd, FRCPC*
- 12.15 Inhibiting crosstalk between estrogen receptor (ER) and PI3K/AKT/ mTOR pathways: What we know and what we would like to know  
*Nicholas Turner, MA, MRCP, PhD*
- 12.30 Challenging patient scenarios from clinical practice in advanced breast cancer  
*Sunil Verma, MD, MEd, FRCPC*  
*Interactive Panel & Audience Discussion*
- 13.00 What does the future hold for PI3K/AKT/mTOR inhibitors in breast cancer?  
*Sara Hurvitz, MD*
- 13.15 Concluding remarks  
*Sunil Verma, MD, MEd, FRCPC*

## Learning Objectives

After successful completion of this educational activity, participants should be able to:

- Describe the role of ER and PI3K/AKT/mTOR signaling in patients with advanced breast cancer
- Evaluate rationale and strategies to inhibit the PI3K/AKT/mTOR pathway
- Discuss optimal treatment options for patients with endocrine therapy-resistant advanced breast cancer
- Discuss the importance of early recognition and management of adverse events, in particular, with novel targeted agents
- Examine ongoing clinical trials with emerging PI3K/AKT/mTOR inhibitors and the unmet need for parallel translational research



This meeting is a prIME Oncology activity.



Support for this educational activity is provided by Novartis Oncology.

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

Register online at: [www.prIMEoncology.org/Breast\\_Brussels](http://www.prIMEoncology.org/Breast_Brussels)